- Data demonstrates that the 100% resolution of lesions
present at baseline is maintained at 48 weeks
LAVAL, QC, Dec. 6, 2017 /CNW Telbec/ - Prometic Life
Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today
announced that it will have two presentations at the 59th American
Society of Hematology (ASH) Annual Meeting being held Dec. 9-12, 2017 in Atlanta.
An oral presentation, entitled, "Pivotal Trial with Intravenous
Plasminogen Replacement in Patients with Plasminogen Deficiency
Demonstrates Long-Term Efficacy for Treatment and Prevention of
Ligneous Lesions" will be presented by Dr. Charles T. Nakar, Indiana Hemophilia and
Thrombosis Center. During the oral session, Dr. Nakar will present
48-week data demonstrating the long-term safety and efficacy of
intravenous plasminogen replacement (RyplazimTM) in
patients with plasminogen deficiency.
A poster presentation, entitled, "Computer Modeling Using
Historical Data Demonstrates a Significant Reduction in Expected
Extravascular Fibrinous Lesions Due to Congenital Plasminogen
Deficiency While Receiving Intravenous Plasminogen Replacement"
will be presented by Dr. Joseph M.
Parker, Senior Director of clinical development of Prometic.
Dr. Parker will present a poster of historical data computer
modeling highlighting the significant treatment effect of
RyplazimTM in reducing the extravascular ligneous
lesions in pediatric and adult subjects with plasminogen
deficiency.
"Data from these presentations demonstrates the remarkable
safety and efficacy profile of plasminogen treatment we have
observed to date," said Pierre
Laurin, Chief Executive Officer at Prometic. "No
currently-available treatment options have demonstrated a complete
resolution of lesions in patients with plasminogen deficiency. We
are continuing to work closely with the FDA with the goal of making
our plasminogen replacement therapy available to patients as soon
as possible."
Details of the oral presentation are as follows:
Presentation Title: Pivotal Trial with Intravenous
Plasminogen Replacement in Patients with Plasminogen Deficiency
Demonstrates Long-Term Efficacy for Treatment and Prevention of
Ligneous Lesions
Presenter: Charles T. Nakar,
M.D.
Session Title: Disorders of Coagulation or Fibrinolysis:
Novel Therapies and Clinical Trials in Bleeding Disorders
Date/Time: Saturday, December 9,
2017 at 9:30 a.m. EST
Room: Georgia World Congress Center, Bldg B, Lvl 2, B207-B208
Details of the poster presentation are as follows:
Presentation Title: Computer Modeling Using Historical
Data Demonstrates a Significant Reduction in Expected Extravascular
Fibrinous Lesions Due to Congenital Plasminogen Deficiency While
Receiving Intravenous Plasminogen (PLG) Replacement
Presenter: Joseph M. Parker,
M.D.
Session Title: Disorders of Coagulation or Fibrinolysis:
Poster II
Date/Time: Sunday, December 10,
2017 from 6:00 p.m. to 8:00 p.m.
EST
Room: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
About Prometic Life Sciences Inc.
Prometic Life
Sciences Inc. (www.prometic.com) is a long-established
biopharmaceutical company with globally recognized expertise in
bioseparations, plasma-derived therapeutics and small-molecule drug
development. Prometic is active in developing its own novel
small-molecule therapeutic products targeting unmet medical needs
in the field of fibrosis, cancer and autoimmune
diseases/inflammation. A number of plasma-derived and small
molecule products are under development for orphan drug
indications. Prometic also offers its state-of-the-art technologies
for large-scale purification of biologics, drug development,
proteomics and the elimination of pathogens to a growing base of
industry leaders and uses its own affinity technology that provides
for highly efficient extraction and purification of therapeutic
proteins from human plasma in order to develop best-in-class
therapeutics and orphan drugs. Headquartered in Laval (Canada), Prometic has R&D facilities
in the UK, the U.S. and Canada, manufacturing facilities in the UK
and commercial activities in the U.S., Canada, Europe and Asia.
Forward Looking
Statements
This press release contains forward-looking statements about
Prometic's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited
to, Prometic's ability to develop, manufacture, and successfully
commercialize value-added pharmaceutical products, the availability
of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of Prometic
to take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or
results to materially differ from our current expectations in
Prometic's Annual Information Form for the year ended December 31, 2016, under the heading "Risk and
Uncertainties related to Prometic's business". As a result,
we cannot guarantee that any forward-looking statement will
materialize. We assume no obligation to update any forward-looking
statement even if new information becomes available, as a result of
future events or for any other reason, unless required by
applicable securities laws and regulations. All amounts are
in Canadian dollars unless indicated otherwise.
SOURCE ProMetic Life Sciences Inc.